{"meshTags":["Androstadienes","Antineoplastic Agents, Hormonal","Aromatase Inhibitors","Breast Neoplasms","Female","Humans","Nitriles","Selective Estrogen Receptor Modulators","Tamoxifen","Triazoles"],"meshMinor":["Androstadienes","Antineoplastic Agents, Hormonal","Aromatase Inhibitors","Breast Neoplasms","Female","Humans","Nitriles","Selective Estrogen Receptor Modulators","Tamoxifen","Triazoles"],"genes":["aromatase","aromatase"],"publicationTypes":["Journal Article","Review"],"abstract":"Endocrine therapy with certain effect is an important part of combined therapy for hormone receptor-positive breast cancer. The endocrine therapy for breast cancer has made progress with the development of new endocrine drugs. Now, tamoxifen is still the standard endocrine therapeutic drug for the premenopausal patients, but aromatase inhibitors can bring more benefit for the postmenopausal patients. Several large-scale clinical trials about aromatase inhibitors and medical ovarian ablation are ongoing and attract attention widely. This review overviewed the endocrine therapy for breast cancer, and mainly introduced its recent advancement.","title":"[Advancement in endocrine therapy for breast cancer].","pubmedId":"17430670"}